依洛尤单抗对ACS患者PCI术后血脂、MHR、NLR的影响  

Effect of evolocumab on the levels of blood lipids,MHR and NLR in ACS patients after percutaneous coronary intervention

作　　者：魏丽媛 江珊[1] WEI Li-yuan;JIANG Shan(Department of Cardiovascular Medicine,Jinzhou Central Hospital,Jinzhou,Liaoning,121000,China)

机构地区：[1]锦州市中心医院心血管内科,辽宁锦州121000

出　　处：《心血管康复医学杂志》2025年第2期236-241,共6页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:分析依洛尤单抗对急性冠脉综合征(ACS)患者经皮冠状动脉介入(PCI)术后血脂、单核细胞与高密度脂蛋白胆固醇比值(MHR)、中性粒细胞与淋巴细胞比值(NLR)的影响。方法:选择2021年12月至2023年9月期间于锦州市中心医院就诊的112例行PCI手术治疗的ACS患者作为研究对象,依照用药情况将患者分为对照组(n=60,接受阿托伐他汀治疗)和联合治疗组(n=52,接受阿托伐他汀联用依洛尤单抗治疗),两组均治疗3个月。比较两组血脂水平、炎症因子、MHR、NLR。结果:治疗后,与对照组比较,联合治疗组总胆固醇(TC)[(3.29±0.78)mmol/L比(3.69±0.85)mmol/L]、低密度脂蛋白胆固醇(LDL-C)[(1.24±0.40)mmol/L比(1.79±0.52)mmol/L]、载脂蛋白B(ApoB)[(73.46±16.21)mg/dl比(93.02±17.13)mg/dl]、高敏C反应蛋白(hsCRP)[(2.16±0.77)mg/L比(2.53±0.89)mg/L]、MHR[(0.25±0.07)×109/mmol比(0.30±0.09)×109/mmol]显著降低(P<0.05或<0.01)。结论:急性冠脉综合征患者经皮冠状动脉介入术后应用依洛尤单抗联合阿托伐他汀治疗对于单核细胞与高密度脂蛋白胆固醇比值和血脂的调控作用显著,且能显著降低炎症因子水平。Objective:To analyze the effect of evolocumab on the levels of blood lipids,monocyte-to-high density lipoprotein cholesterol ratio(MHR)and neutrophil-to-lymphocyte ratio(NLR)in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods:We enrolled 112 ACS patients who underwent PCI in Jinzhou Central Hospital between December 2021 and September 2023.According to medication,the patients were divided into control group(n=60,atorvastatin therapy)and combined treatment group(n=52,atorvastatin combined with evolocumab therapy),both groups were treated for 3 months.Blood lipids,inflammatory factors,MHR and NLR were compared between two groups.Results:Compared with patients in control group after treatment,those in combined treatment group had significant lower total cholesterol(TC)[(3.29±0.78)mmol/L vs.(3.69±0.85)mmol/L],low density lipoprotein cholesterol(LDL-C)[(1.24±0.40)mmol/L vs.(1.79±0.52)mmol/L],apolipoprotein B(ApoB)[(73.46±16.21)mg/ml vs.(93.02±17.13)mg/ml],high sensitive C-reactive protein(hsCRP)[(2.16±0.77)mg/L vs.(2.53±0.89)mg/L]and MHR[(0.25±0.07)×109/mmol vs.(0.30±0.09)×109/mmol](P<0.05 or<0.01).Conclusion:Evolocumab combined with atorvastatin possesses a significant regulating effecton monocyte-to-highdensity lipoprotein cholesterol ratio and blood lipids,and significantly reduces inflammatory factor levels in patients with acute coronary syndrome after percutaneous coronary intervention.

关 键 词：急性冠脉综合征 血管成形术 气囊 冠状动脉 依洛尤单抗 

分 类 号：R541.4[医药卫生—心血管疾病]